Akari Therapeutics

Revenue, earnings, and free cash flow are zero or negative and driven by financing cadence rather than operations. The lead program is preclinical with first‑in‑human targeted for mid‑2027, which introduces multi‑year binary risk on IND clearance, dose finding, safety, and early efficacy.

Competitive read‑throughs in Trop2 suggest viable demand if successful, but timelines, regulatory outcomes, and capital access inject high uncertainty. Geographic diversification and payer mix are irrelevant until approval. Overall predictability is very low at this stage.